Context

Type 2 diabetes has high long-team health and resource impact, as a result of its vascular complications and needed therapies. Prevention of diabetes then seems to be attractive. Previous studies have identified that lifestyle interventions and some therapeutic approaches can prevent or delay the onset of diabetes in those with hyperglycaemia. Such therapies include metformin and thiazolidinediones. Metformin and rosiglitazone are efficacious in combination in people with diabetes, while tablet combination at submaximum dose may give additive effects with reduced side effects. Zinman and colleagues asked whether such combination of these agents could prevent deterioration to diabetes in a population at risk.